Development code · Small Molecule
BTRX-323511
BTRX-323511 is a development code for NMRA-511, developed by Neumora Therapeutics, Inc..
- Status
- Phase 1 for Agitation in Alzheimer's disease
- Mechanism
- V1a receptor Antagonist
- Developer
- Neumora Therapeutics, Inc.
Programs
- NMRA-511 for Agitation in Alzheimer's diseasePhase 1Active
Also known as
- NMRA-511
- NMRA-323511